Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus METHYLPREDNISOLONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus METHYLPREDNISOLONE ACETATE.
DEXASPORIN vs METHYLPREDNISOLONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Methylprednisolone acetate is a synthetic glucocorticoid that binds to the glucocorticoid receptor, modulating gene expression to suppress inflammation, immune response, and adrenal function. It inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis, and decreases cytokine production.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
40-80 mg intramuscular (IM) or intra-articular (IA) injection; for IM use, dose may be repeated every 1-4 weeks as needed. Maximum single IM dose: 120 mg.
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Terminal half-life: 3-3.5 hours; correlates with duration of anti-inflammatory effect due to receptor-mediated action.
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal: <10% unchanged; extensive hepatic metabolism to inactive metabolites primarily excreted renally as glucuronides and sulfates.
Category C
Category D/X
Corticosteroid/Antibiotic Combination
Corticosteroid